Amisulpride is a dopamine D2 receptor antagonist indicated for the treatment of acute and chronic schizophrenia characterized by positive symptoms (e.g., delusions, hallucinations, thought disorders) and/or negative symptoms (e.g., affective apathy, affective and social withdrawal), including patients in whom negative symptoms are predominant.

Amisulpride dosing guidelines for acute psychotic episodes recommend 400-800 mg/day orally, with a possibility to increase up to 1200 mg/day in individual cases. However, doses exceeding 1200 mg/day are not advised due to safety concerns, and those above 800 mg/day may not offer additional benefits but could raise the risk of adverse events. There's no need for titration when starting treatment, and dosing should be personalized and preferably taken before meals. For doses above 400 mg, administration twice daily is suggested. In patients with mixed symptoms, adjust dosing for optimal positive symptom control, and establish maintenance treatment with the minimal effective dose. For predominant negative symptoms, 50-300 mg/day is advised, with individual adjustments. Caution is needed in the elderly due to potential hypotension or sedation risks. Amisulpride is contraindicated in children up to puberty. In renal insufficiency, dosing should be reduced based on creatinine clearance levels, with no established guidance for severe impairment (CRCL < 10 mL/min). No dosage adjustment is typically needed for hepatic insufficiency due to its minimal metabolism.